Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431838 | 0.86 | — | — | |
| SCHEMBL2062290 | 0.82 | PPARA (0.36) | TLR7TLR8KDM4ERAB9AALDH1A1 | |
| SCHEMBL11646525 | 0.81 | TLR7 (0.36) | TLR7TLR8KDM4ERAB9AALDH1A1 | |
| SCHEMBL5538019 | 0.78 | TDP1 (0.35) | TLR7TLR8KDM4ERAB9AALDH1A1 | |
| SCHEMBL5539508 | 0.78 | TLR7 (0.33) | TLR7TLR8MAPTTDP1L3MBTL1 | |
| SCHEMBL6431266 | 0.77 | — | — | |
| SCHEMBL5538016 | 0.77 | TDP1 (0.34) | TLR7TLR8KDM4ERAB9AALDH1A1 | |
| SCHEMBL1520366 | 0.77 | TDP1 (0.34) | TLR7TLR8KDM4ERAB9AALDH1A1 | |
| SCHEMBL3733911 | 0.77 | SIRT2 (0.37) | TLR7TLR8MAPTTDP1L3MBTL1 | |
| SCHEMBL5536581 | 0.77 | MAPT (0.37) | TLR7KDM4ERAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
| EP-1432687-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| WO-2003093242-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-7105559-B2 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097113-A2 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| WO-2005016338-A1 | USE OF 5-HT2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1482940-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1432687-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003093242-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| CN-1126208-A | 2-amido-5-aryl-1,3,4-oxdiazole compound, its synthesis and application | HUADONG SCIENCE & ENGINEERING (CN) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | TLR7 1328/4885TLR8 2635/4885KDM4E 2758/4885 |
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | TLR7 3696/4885TLR8 3457/4885KDM4E 2216/4885 |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | TLR7 3696/4885TLR8 3457/4885KDM4E 2216/4885 |
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | TLR7 490/4885TLR8 1709/4885KDM4E 3337/4885 |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | TLR7 4001/4885TLR8 3175/4885KDM4E 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.